Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 4/20 | 0.47 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.46 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 4/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2773467 | 0.93 | KDM4E (0.50) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL2774189 | 0.91 | KDM4E (0.49) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL2777190 | 0.85 | ALDH1A1 (0.44) | KDM4EMEN1MAPTKMT2ACNR1 | |
| SCHEMBL496088 | 0.85 | CNR2 (0.49) | CNR1CNR2 | |
| SCHEMBL495958 | 0.81 | CNR2 (0.61) | CNR1CNR2 | |
| SCHEMBL2911118 | 0.81 | CNR2 (0.66) | CNR1CNR2 | |
| SCHEMBL2906584 | 0.81 | CNR2 (0.57) | CNR1CNR2 | |
| SCHEMBL7295117 | 0.80 | CNR2 (0.42) | CNR1CNR2 | |
| SCHEMBL496033 | 0.79 | CNR2 (0.48) | CNR1CNR2 | |
| SCHEMBL496092 | 0.79 | CNR2 (0.53) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088751-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENCZE PHARMANESS S.C. A R.L. (IT) | 2012-04-12 | — | — | US | disclosed |
| US-20120088751-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENCZE PHARMANESS S.C. A R.L. (IT) | 2012-04-12 | — | — | US | disclosed |
| US-8106218-B2 | Pharmaceutical compounds | NEUROSCIENZE PHARMANESS S.C. A R.L. (IT) | 2012-01-31 | — | — | US | disclosed |
| US-8106218-B2 | Pharmaceutical compounds | NEUROSCIENZE PHARMANESS S.C. A R.L. (IT) | 2012-01-31 | — | — | US | disclosed |
| EP-1602658-B1 | Tricyclic pyrazole derivatives as cannabinoid receptor antagonists | NEUROSCIENZE PHARMANESS S C A R L (IT) | 2011-12-07 | — | — | EP | disclosed |
| US-20090081123-A1 | PHARMACEUTICAL COMPOUNDS | CENERX BIOPHARMA (US) | 2009-03-26 | — | — | US | disclosed |
| US-20090081123-A1 | PHARMACEUTICAL COMPOUNDS | CENERX BIOPHARMA (US) | 2009-03-26 | — | — | US | disclosed |
| US-7485730-B2 | Pharmaceutical compounds | NEUROSCIENZE PHARMANESS S.C. A R.L. (IT) | 2009-02-03 | — | — | US | disclosed |
| US-7485730-B2 | Pharmaceutical compounds | NEUROSCIENZE PHARMANESS S.C. A R.L. (IT) | 2009-02-03 | — | — | US | disclosed |
| EP-1602658-A1 | Tricyclic pyrazole derivatives as cannabinoid receptor antagonists | Neuroscienze Oharmaness S.c.a.r.l. (IT) | 2005-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088751-A1 | PHARMACEUTICAL COMPOUNDS | CNR2, CNR1, OPRK1 | KDM4E 581/4885MEN1 4563/4885MAPT 2961/4885 |
| US-20090081123-A1 | PHARMACEUTICAL COMPOUNDS | CNR2, CNR1, OPRK1 | KDM4E 582/4885MEN1 4591/4885MAPT 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.